Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbinoxamine
Drug ID BADD_D00361
Description Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.
Indications and Usage For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
Marketing Status approved
ATC Code R06AA08
DrugBank ID DB00748
KEGG ID D07617
MeSH ID C004649
PubChem ID 2564
TTD Drug ID D00FGV
NDC Product Code Not Available
UNII 982A7M02H5
Synonyms carbinoxamine | Histex PD | Histex I-E | carbinoxamine maleate | Histex CT
Chemical Information
Molecular Formula C16H19ClN2O
CAS Registry Number 486-16-8
SMILES CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Asthenia08.01.01.001---
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.002---
Chills08.01.09.001; 15.05.03.016--
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Conversion disorder19.24.01.001---
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001---
Dyspepsia07.01.02.001--
Euphoric mood19.04.02.006--
Extrasystoles02.03.02.003---
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Haemolytic anaemia01.06.03.002---
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypotension24.06.03.002--
Insomnia17.15.03.002; 19.02.01.002--
Irritability08.01.03.011; 19.04.02.013--
Labyrinthitis04.04.03.001; 11.01.05.002---
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervousness19.06.02.003---
Neuritis17.09.03.001---
Neuropathy peripheral17.09.03.003---
Palpitations02.11.04.012--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene